{"id":20954,"date":"2021-05-05T11:03:33","date_gmt":"2021-05-05T11:03:33","guid":{"rendered":"https:\/\/neuraxpharm.com\/it\/portfolio\/lazapir"},"modified":"2022-02-16T14:29:39","modified_gmt":"2022-02-16T14:29:39","slug":"lazapir","status":"publish","type":"portfolio-products","link":"https:\/\/www.neuraxpharm.com\/it\/portfolio\/lazapir","title":{"rendered":"Lazapir"},"content":{"rendered":"<p><strong>Trattamento della schizofrenia<\/strong><\/p>\n<p>Nei pazienti che hanno dimostrato risposta positiva al trattamento iniziale, il proseguimento della terapia con olanzapina consente di mantenere il miglioramento clinico.<\/p>\n<p><strong>Trattamento dell\u2019episodio di mania da moderato a grave<\/strong><\/p>\n<p>Nei pazienti in cui l\u2019episodio maniacale ha risposto al trattamento con olanzapina, l\u2019olanzapina \u00e8 indicata per la prevenzione dei nuovi episodi di malattia in pazienti con disturbo bipolare.<\/p>\n<p>&nbsp;<\/p>\n<p>LAZAPIR &#8211; Olanzapina &#8211; 5 MG &#8211; 28 compresse orodispersibili \u2013 Prezzo al pubblico 19,50 \u20ac; Classe A; RR<\/p>\n<p>LAZAPIR &#8211; Olanzapina &#8211; 10 MG &#8211; 28 compresse orodispersibili \u2013 Prezzo al pubblico 33,50 \u20ac; Classe A; RR<\/p>\n<p>Cod. NRX\/100 &#8211; Depositato presso AIFA in data 25\/05\/2021<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"featured_media":18861,"parent":0,"template":"","active-substance":[185],"product-category":[173],"therapeutic-area":[227,226],"class_list":["post-20954","portfolio-products","type-portfolio-products","status-publish","has-post-thumbnail","hentry","active-substance-olanzapina","product-category-linea-farmaceutica","therapeutic-area-disturbo-bipolare","therapeutic-area-schizofrenia"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.2 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Lazapir - Neuraxpharm Italia<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.neuraxpharm.com\/it\/portfolio\/lazapir\" \/>\n<meta property=\"og:locale\" content=\"it_IT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lazapir\" \/>\n<meta property=\"og:description\" content=\"Trattamento della schizofrenia Nei pazienti che hanno dimostrato risposta positiva al trattamento iniziale, il proseguimento della terapia con olanzapina consente di mantenere il miglioramento clinico. Trattamento dell\u2019episodio di mania da moderato a grave Nei pazienti in cui l\u2019episodio maniacale ha risposto al trattamento con olanzapina, l\u2019olanzapina \u00e8 indicata per la prevenzione dei nuovi episodi di [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.neuraxpharm.com\/it\/portfolio\/lazapir\" \/>\n<meta property=\"og:site_name\" content=\"Neuraxpharm Italia\" \/>\n<meta property=\"article:modified_time\" content=\"2022-02-16T14:29:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.neuraxpharm.com\/it\/wp-content\/uploads\/sites\/5\/2021\/04\/lazapir-10.png\" \/>\n\t<meta property=\"og:image:width\" content=\"920\" \/>\n\t<meta property=\"og:image:height\" content=\"960\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tempo di lettura stimato\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.neuraxpharm.com\/it\/portfolio\/lazapir\",\"url\":\"https:\/\/www.neuraxpharm.com\/it\/portfolio\/lazapir\",\"name\":\"Lazapir - Neuraxpharm Italia\",\"isPartOf\":{\"@id\":\"https:\/\/www.neuraxpharm.com\/it\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.neuraxpharm.com\/it\/portfolio\/lazapir#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.neuraxpharm.com\/it\/portfolio\/lazapir#primaryimage\"},\"thumbnailUrl\":\"https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2021\/04\/lazapir-10.png\",\"datePublished\":\"2021-05-05T11:03:33+00:00\",\"dateModified\":\"2022-02-16T14:29:39+00:00\",\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.neuraxpharm.com\/it\/portfolio\/lazapir\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\/\/www.neuraxpharm.com\/it\/portfolio\/lazapir#primaryimage\",\"url\":\"https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2021\/04\/lazapir-10.png\",\"contentUrl\":\"https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2021\/04\/lazapir-10.png\",\"width\":920,\"height\":960},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.neuraxpharm.com\/it\/#website\",\"url\":\"https:\/\/www.neuraxpharm.com\/it\/\",\"name\":\"Neuraxpharm Italia\",\"description\":\"A European Leader for the CNS products\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.neuraxpharm.com\/it\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"it-IT\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lazapir - Neuraxpharm Italia","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.neuraxpharm.com\/it\/portfolio\/lazapir","og_locale":"it_IT","og_type":"article","og_title":"Lazapir","og_description":"Trattamento della schizofrenia Nei pazienti che hanno dimostrato risposta positiva al trattamento iniziale, il proseguimento della terapia con olanzapina consente di mantenere il miglioramento clinico. Trattamento dell\u2019episodio di mania da moderato a grave Nei pazienti in cui l\u2019episodio maniacale ha risposto al trattamento con olanzapina, l\u2019olanzapina \u00e8 indicata per la prevenzione dei nuovi episodi di [&hellip;]","og_url":"https:\/\/www.neuraxpharm.com\/it\/portfolio\/lazapir","og_site_name":"Neuraxpharm Italia","article_modified_time":"2022-02-16T14:29:39+00:00","og_image":[{"width":920,"height":960,"url":"https:\/\/www.neuraxpharm.com\/it\/wp-content\/uploads\/sites\/5\/2021\/04\/lazapir-10.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Tempo di lettura stimato":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.neuraxpharm.com\/it\/portfolio\/lazapir","url":"https:\/\/www.neuraxpharm.com\/it\/portfolio\/lazapir","name":"Lazapir - Neuraxpharm Italia","isPartOf":{"@id":"https:\/\/www.neuraxpharm.com\/it\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.neuraxpharm.com\/it\/portfolio\/lazapir#primaryimage"},"image":{"@id":"https:\/\/www.neuraxpharm.com\/it\/portfolio\/lazapir#primaryimage"},"thumbnailUrl":"https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2021\/04\/lazapir-10.png","datePublished":"2021-05-05T11:03:33+00:00","dateModified":"2022-02-16T14:29:39+00:00","inLanguage":"it-IT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.neuraxpharm.com\/it\/portfolio\/lazapir"]}]},{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/www.neuraxpharm.com\/it\/portfolio\/lazapir#primaryimage","url":"https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2021\/04\/lazapir-10.png","contentUrl":"https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2021\/04\/lazapir-10.png","width":920,"height":960},{"@type":"WebSite","@id":"https:\/\/www.neuraxpharm.com\/it\/#website","url":"https:\/\/www.neuraxpharm.com\/it\/","name":"Neuraxpharm Italia","description":"A European Leader for the CNS products","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.neuraxpharm.com\/it\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"it-IT"}]}},"acf":[],"_links":{"self":[{"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/portfolio-products\/20954","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/portfolio-products"}],"about":[{"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/types\/portfolio-products"}],"version-history":[{"count":11,"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/portfolio-products\/20954\/revisions"}],"predecessor-version":[{"id":25667,"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/portfolio-products\/20954\/revisions\/25667"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/media\/18861"}],"wp:attachment":[{"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/media?parent=20954"}],"wp:term":[{"taxonomy":"active-substance","embeddable":true,"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/active-substance?post=20954"},{"taxonomy":"product-category","embeddable":true,"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/product-category?post=20954"},{"taxonomy":"therapeutic-area","embeddable":true,"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/therapeutic-area?post=20954"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}